The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | TRIANGLE: ibrutinib with SOC or as a substitute to autologous transplantation in first-line MCL
Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, gives an overview of the results of the TRIANGLE study (EudraCT 2014-001363-12) which evaluated the efficacy and safety of adding ibrutinib to standard autologous transplantation or used as a substitute to transplantation in young patients with mantle cell lymphoma (MCL) in the first-line setting. Overall, the study showed a failure-free survival (FFS) benefit in ibrutinib-containing arms, thereby questioning the current standard of care (SOC). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
TG Therapeutics: Consultancy, Research Funding; Genentech: Consultancy, Other: DMC, Research Funding; Novartis: Research Funding; Abbvie: Consultancy; AstraZeneca: Consultancy; BMS: Consultancy; Adaptive Technologies: Consultancy; ADC Therapeutics: Consultancy; Beigene: Consultancy; Impact Bio: Consultancy; SeaGen: Speakers Bureau; Celgene: Other: DMC.
